155 related articles for article (PubMed ID: 30654495)
1. Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis.
Connelly S; Parsley T; Ge H; Kaleko M
Microorganisms; 2019 Jan; 7(1):. PubMed ID: 30654495
[TBL] [Abstract][Full Text] [Related]
2. Oral Metallo-Beta-Lactamase Protects the Gut Microbiome From Carbapenem-Mediated Damage and Reduces Propagation of Antibiotic Resistance in Pigs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Front Microbiol; 2019; 10():101. PubMed ID: 30804903
[TBL] [Abstract][Full Text] [Related]
3. Oral Beta-Lactamase Protects the Canine Gut Microbiome from Oral Amoxicillin-Mediated Damage.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Microorganisms; 2019 May; 7(5):. PubMed ID: 31137766
[TBL] [Abstract][Full Text] [Related]
4. SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Microorganisms; 2020 Jan; 8(2):. PubMed ID: 31979034
[TBL] [Abstract][Full Text] [Related]
5. SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model.
Connelly S; Bristol JA; Hubert S; Subramanian P; Hasan NA; Colwell RR; Kaleko M
J Appl Microbiol; 2017 Jul; 123(1):66-79. PubMed ID: 28245091
[TBL] [Abstract][Full Text] [Related]
6. The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.
Kokai-Kun JF; Roberts T; Coughlin O; Sicard E; Rufiange M; Fedorak R; Carter C; Adams MH; Longstreth J; Whalen H; Sliman J
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052855
[TBL] [Abstract][Full Text] [Related]
7. Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
AIMS Public Health; 2019; 6(4):477-487. PubMed ID: 31909068
[TBL] [Abstract][Full Text] [Related]
8. Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
Kaleko M; Bristol JA; Hubert S; Parsley T; Widmer G; Tzipori S; Subramanian P; Hasan N; Koski P; Kokai-Kun J; Sliman J; Jones A; Connelly S
Anaerobe; 2016 Oct; 41():58-67. PubMed ID: 27262694
[TBL] [Abstract][Full Text] [Related]
9. Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics.
Kokai-Kun JF; Bristol JA; Setser J; Schlosser M
Int J Toxicol; 2016 May; 35(3):309-16. PubMed ID: 26700136
[TBL] [Abstract][Full Text] [Related]
10. Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone.
Kokai-Kun JF; Le C; Trout K; Cope JL; Ajami NJ; Degar AJ; Connelly S
Infect Drug Resist; 2020; 13():2521-2535. PubMed ID: 32801790
[TBL] [Abstract][Full Text] [Related]
11. Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon.
Bristol A; Hubert S; Hofmann F; Baer H
Int J Pharm; 2017 Dec; 534(1-2):25-34. PubMed ID: 28986322
[TBL] [Abstract][Full Text] [Related]
12. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
[TBL] [Abstract][Full Text] [Related]
13.
Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
[TBL] [Abstract][Full Text] [Related]
14. Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome.
Connelly S; Subramanian P; Hasan NA; Colwell RR; Kaleko M
Anaerobe; 2018 Oct; 53():82-93. PubMed ID: 29689301
[TBL] [Abstract][Full Text] [Related]
15. Characterization of novel plasmid-mediated β-lactamases (SHV-167 and ACT-16) associated with New Delhi metallo-β-lactamase-1 harbouring isolates from neonates in India.
Datta S; Mitra S; Viswanathan R; Saha A; Basu S
J Med Microbiol; 2014 Mar; 63(Pt 3):480-482. PubMed ID: 24336426
[TBL] [Abstract][Full Text] [Related]
16. Carbapenemase-producing Enterobacteriaceae: overview of a major public health challenge.
Nordmann P
Med Mal Infect; 2014 Feb; 44(2):51-6. PubMed ID: 24360201
[TBL] [Abstract][Full Text] [Related]
17. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
18. [MULTIRESISTANT BACTERIA].
Bedenić B; Sardelić S; Ladavac M
Acta Med Croatica; 2015 Sep; 69(3):211-6. PubMed ID: 29077379
[TBL] [Abstract][Full Text] [Related]
19. Resistotyping, phenotyping and genotyping of New Delhi metallo-β-lactamase (NDM) among Gram-negative bacilli from Iranian patients.
Shokri D; Rabbani Khorasgani M; Fatemi SM; Soleimani-Delfan A
J Med Microbiol; 2017 Apr; 66(4):402-411. PubMed ID: 28150578
[TBL] [Abstract][Full Text] [Related]
20. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
Stock I
Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
